# Connect® Myeloid Disease Registry

> **NCT01688011** · — · TERMINATED · sponsor: **Celgene** · enrollment: 2013 (actual)

## Conditions studied

- Primary Myelofibrosis
- Myelodysplastic Syndromes
- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** Luspatercept

## Key facts

- **NCT ID:** NCT01688011
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2013-12-12
- **Primary completion:** 2024-10-18
- **Final completion:** 2024-10-18
- **Target enrollment:** 2013 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01688011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01688011, "Connect® Myeloid Disease Registry". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01688011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*